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Abstract
Background: Pembrolizumab is an anti- Programmed Death 1 (PD-1) antibody approved in melanoma, non-small
cell lung cancer and investigated in malignant pleural mesothelioma.
The most frequent immunotherapy related autoimmune reactions include dermatitis, pneumonitis, colitis,
hypophysitis, uveitis, hypothyreodism, hepatitis and interstitial nephritis.
Case presentation: We describe a 62-year old patient diagnosed with malignant pleural mesothelioma who
experienced ten days after the second dose of third line therapy with pembrolizumab sudden onset of generalized
edema including legs and eyelids and weight gain of 15 kg resulting from nephrotic syndrome and acute renal
failure. Pembrolizumab was discontinued and prednisone, diuretics and angiotensin II receptor blocker were
initiated with full recovery of symptoms and renal function. Pembrolizumab-associated minimal change disease
(MCD) was confirmed by electron microscopy in the renal biopsy.
Conclusion: We are the first to describe pembrolizumab-related minimal change disease (MCD).
Physicians should be aware of this side effect in patients presenting with edema and weight gain and initiate
prompt renal function testing, serum albumin and urinalysis followed by steroid treatment if pembrolizumab-
related MCD is suspected.
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Case presentation
A 62-year old patient was diagnosed with malignant bi-
phasic pleural mesothelioma in June 2014. He experi-
enced progressive disease after six cycles of carboplatin/
pemetrexed and six cycles of second line vinorelbine.
Ten days after the second dose of 200 mg of a third line
therapy with pembrolizumab sudden onset of general-
ized edema including the legs and eyelids with weight
gain of 15 kg occurred. Nephrotic syndrome with pro-
teinuria of 19 g per day, hypoalbuminemia (15 g/l) and
hypercholesterolemia of 7.8 mmol/l was diagnosed
followed by acute renal failure with a rapid deterioration
of the estimated glomerular filtration rate from > 90 to
28 ml/min/1.73 m2. Pembrolizumab was discontinued
due to suspected immune-related renal toxicity and
prednisone (1 mg/kg/ day), diuretics and an angiotensin
II receptor blocker was initiated. A renal biopsy showed
diffuse fusions of the epithelial foot processes on electron
microscopy compatible with minimal change disease
(MCD) (Fig. 1). Direct immunofluorescence microscopy
was negative with no complement or immunoglobulin
deposits. Within 5 weeks, creatinine values normalized
and the proteinuria resolved. The patient reported on
symptomatic relief of disease-associated chest pain and
currently remains in stable condition without systemic
therapy 10 weeks later.
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Background and Conclusion
Pembrolizumab is an anti- Programmed Death 1 (PD-1)
antibody approved for advanced melanoma that progressed
following ipilimumab and, if BRAF[V600] mutant, a BRAF
inhibitor and for PD-L (ligand) 1 positive advanced non-
small cell lung cancer after progression to standard
platinum based firstline treatment. It is investigated in mul-
tiple cancers including malignant pleural mesothelioma.
Preliminary results of a single arm trial with 25 pretreated
PD-L1- positive mesothelioma patients demonstrated an
encouraging response rate of 28 %, a disease control rate of
76 % including durable response rates and a progression
free survival rate at 6 months of 49 % [1]. Pembrolizumab
disrupts the engagement of PD-1 with its ligands and
impedes inhibitory signals leading to recognition of tumor
cells by cytotoxic T cells. Immune related-adverse events
such as dermatitis, hypophysitis, colitis and hepatitis have
been reported for this class of agents. Whereas interstitial
nephritis is a rare, but a well-recognised serious renal side
effect, MCD has not been described in this context. Early
trials with pembrolizumab have reported grade 3 and 4
edema in two patients [2] without further specification of
the underlying cause. In our patient, clinical signs of
nephrotic syndrome with hypovolemic acute renal failure
and histologic findings on electron microscopy confirmed
the diagnosis. MCD mainly occurs in conditions with acti-
vated adaptive immune system such as in young children,
hematologic malignancies and autoimmune diseases. The
pathology of MCD is poorly understood. Alterations of
regulatory T-cells or their differentiation, epigenetic mecha-
nisms and up-regulated secretion of proteins by podocytes
may play an etiologic role. Typically, no specific changes
are notable on light microscopy (ie the term “minimal
change”), electron microscopy almost always shows loss of
podocytes or at least a change of podocyte architecture.
MCD has also recently been described in a patient receiving
ipilimumab and in mesothelioma patients in the absence of
immunotherapy [3, 4]. Whether a structural and functional
similarity of podocytes and mesothelial cells increases the
risk of MCD with immunotherapy in this particular patient
population would have to be further investigated.
To the best of our knowledge, this is the first case of a
pembrolizumab- associated MCD resulting in nephrotic
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Fig. 1 Electron microscopy. Glomerular capillary loops with findings of minimal change disease: Podocytes with extensive, diffuse foot process
effacement (with arrows) and microvillous transformation. No electron-dense deposits. Normal thickness of glomerular basement membrane.
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